Cambridge's Foundation Medicine launches drug collaboration

Foundation Medicine Inc. and Clovis Oncology Inc. said today they will work together to develop an in-vitro test for identifying biomarkers in specific cancer patients who would most likely respond to a Clovis drug.

The companies said they will analyze the genomic alterations found in tissue samples from patients to evaluate the feasibility of developing an in-vitro diagnostic method to identify patients, including those with ovarian cancer, with tumors most likely to respond to the drug rucaparib.

Foundation Medicine is a Cambridge-based molecular information company. Clovis, a biopharmaceutical company, is based in Boulder, Colo.

Foundation Medicines core capability is the translation of genomic insights into clinically actionable information, said company president and CEO Michael Pellini. But even the most in-depth genomic profile for a patient is only as actionable as the available and relevant targeted therapies. Therefore, we are working to help expand the universe of targeted therapeutic options. Clovis Oncology, a recognized leader in patient specific oncology drug development, is an ideal partner in this mission.

Read the original here:

Cambridge's Foundation Medicine launches drug collaboration

Related Posts

Comments are closed.